{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06507930",
            "orgStudyIdInfo": {
                "id": "24-142"
            },
            "organization": {
                "fullName": "Dana-Farber Cancer Institute",
                "class": "OTHER"
            },
            "briefTitle": "The COMPASSION Study",
            "officialTitle": "The COMPASSION Study: Applying Telehealth to Innovate and Strengthen Connections for Patients With Metastatic Breast Cancer Receiving Hospice Care",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "the-compassion-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2025-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-12",
            "studyFirstSubmitQcDate": "2024-07-12",
            "studyFirstPostDateStruct": {
                "date": "2024-07-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Claire Smith",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Dana-Farber Cancer Institute"
            },
            "leadSponsor": {
                "name": "Dana-Farber Cancer Institute",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.",
            "detailedDescription": "The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.\n\nStudy procedures include giving verbal consent to participate and a one-time survey delivered by email or phone call.\n\nAbout 200 people, which includes 50 participants, 50 caregivers, 50 hospice nurses, and about 50 oncology providers, are expected to participate in this research study."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer",
                "Metastatic Breast Cancer",
                "Advanced Breast Cancer",
                "Unresectable Breast Carcinoma"
            ],
            "keywords": [
                "Breast Cancer",
                "Metastatic Breast Cancer",
                "Advanced Breast Cancer",
                "Unresectable Breast Cancer",
                "Hospice Care"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Usual Care Cohort",
                    "type": "NO_INTERVENTION",
                    "description": "25 participants will complete study procedures as follows:\n\n* Introduction to study and survey by brief, verbal consent via phone call.\n* At 4-6 weeks: survey completion via email or phone."
                },
                {
                    "label": "Compassion Cohort",
                    "type": "EXPERIMENTAL",
                    "description": "25 participants will complete study procedures as follows:\n\n* Introduction to study and survey by brief, verbal consent via phone call.\n* At 4-6 weeks: survey completion via email or phone.\n* 4 weekly check-ins via Zoom or phone call with study team.",
                    "interventionNames": [
                        "Other: Telehealth Hospice Visits"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Telehealth Hospice Visits",
                    "description": "Telehealth check-in appointments with oncology care team, MD, PA, NP, or hospice nurse, via HIPAA compliant telehealth platform, Zoom, or by phone call.",
                    "armGroupLabels": [
                        "Compassion Cohort"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Proportion of Participant Intervention Completion",
                    "description": "Feasibility of the telehealth intervention is defined as greater than or equal to 80% of enrolled participants (18 out of 25) completing greater than or equal to 66% of the planned telehealth check-ins while the participant remains alive.",
                    "timeFrame": "Up to 4 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient of any gender with unresectable locally advanced or metastatic breast cancer\n* Eligible for in-home hospice services and referred by DFCI clinical team to in-home hospice \\</= 1 week before enrollment\n* Ability to conduct video or phone check-ins, even if assistance required.\n* Able to provide verbal consent with a willingness to take a survey at 4-6 weeks, if medically able\n* Hospice setting is within Massachusetts\n* Non-English language allowed but interpreter services must be present at each meeting and will be coordinated by scheduling team\n* Willingness to provide a caregiver/loved one's contact information for survey contact at 4 weeks after enrollment\n\nExclusion Criteria:\n\n* Unable to provide verbal consent\n* Hospice care planned outside of a home setting (note: if participants start out in a home hospice setting but later transition their hospice care to an inpatient setting, enrollment is allowed as long as they started in a home setting)\n* Hospice setting outside of Massachusetts\n* Individuals who are under the age of 18, as this is not a project focused on pediatric patients.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Claire Smith, MD",
                    "role": "CONTACT",
                    "phone": "617-632-3800",
                    "email": "claire_smith@dfci.harvard.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Claire Smith, MD",
                    "affiliation": "Dana-Farber Cancer Institute",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Dana-Farber Cancer Institute",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Claire Smith, MD",
                            "role": "CONTACT",
                            "phone": "617-632-3800",
                            "email": "claire_smith@dfci.harvard.edu"
                        },
                        {
                            "name": "Claire Smith, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \\[contact information for Sponsor Investigator or designee\\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "timeFrame": "Data can be shared no earlier than 1 year following the date of publication",
            "accessCriteria": "Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}